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Abstract
Background: Invossa™ (TissueGene-C) is a cell and gene therapy for osteoarthritis. It is composed of primary human
chondrocytes (hChonJ cells) and irradiated human chondrocytes modified to express TGF-β1 (hChonJb#7 cells).
The hChonJ cells were isolated from a polydactyly donor, and TGF-β1 cDNA was delivered to the cells, generating
hChonJb#7 cells. Since the cells are allogeneic, the concern of immune response against cells has been raised. In this
study, we investigated the immunogenicity of allogenic human chondrocyte, hChonJ cells.
Methods: The immunological properties of hChonJ cells were investigated through the analysis of surface marker
expression and the effect on allogeneic T cell proliferation. Flow cytometry and RT-PCR analysis were performed to
analyze the surface marker expression related to immune response, such as major histocompatibility complex (MHC)
class I, class II, T cell co-stimulatory molecules and T cell co-inhibitory molecules. A mixed lymphocyte reaction (MLR)
was conducted to evaluate how allogeneic T cells would respond to hChonJ cells.
Results: We observed that hChonJ cells did not express MHC class II and T cell co-stimulatory molecules, but expressed
T cell co-inhibitory molecule PD-L2. IFN-γ treatment induced the expression of PD-L1, and up-regulated the expression of
PD-L2. Also, we observed that hChonJ cells did not stimulate T cell proliferation from a MHC-mismatched donor. Further,
they could suppress the proliferation of activated T cells. We also observed that the blockade of PD-L1 and/or PD-L2 with
specific neutralizing antibody could lead to the restoration of allo-reactive T cell proliferation.
Conclusions: We showed that hChonJ cells were not immunogenic but immunosuppressive, and that this phenomenon
was mediated by co-inhibitory molecules PD-L1 and PD-L2 on hChonJ cells in a contact-dependent manner.
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Background
Invossa™ (TissueGene-C) is a cell and gene medicine for
osteoarthritis [1–3]. It is a mixture of primary human
chondrocytes (hChonJ cells) and irradiated human chon-
drocytes modified to express TGF-β1 (hChonJb#7 cells)
by the ratio of 3:1, and is administered into a knee joint
of patients. The components of Invossa™, hChonJ and
hChonJb#7 cells are allogeneic. The hChonJ cells were
isolated from a cartilage of a 1-year-old female poly-
dactyly donor and expanded in a monolayer culture.
TGF-β1 cDNA was transferred to the hChonJ cells using
retroviral vector to generate hChonJb#7 cells. Therefore,
there has been a concern that these cells could induce
immune responses when injected to patient’s joints. To
address this question, the efficacy and safety of Invossa™
was evaluated in several animal models [4–6]. Invossa™
showed efficacy in xenogeneic animals, and no adverse
reaction related to Invossa™ was observed. Based on
these data, clinical trials have been initiated. Up until
now, Invossa™ has been administered more than 200
patients in several clinical trials, but no serious adverse
events related to the cell components have been re-
ported [7–10]. However, no scientific evidence that
Invossa™ does not induce immune response has been
provided so far.
Clinical experiences over the last 30 years have shown
that osteochondral allograft transplantation does not
elicit immune response [11, 12]. In addition, there are a
volume of reports showing that transplanted allogeneic
chondrocytes are not rejected. Transplanted osteochon-
dral graft expresses donor MHC molecules, the primary
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target of the immune response to allogeneic tissues.
Usually, transplanted tissue is rejected when the recipi-
ent T cells recognize donor tissue as non-self, and this
process is mediated by MHC molecules present on the
surface of donor cells. However, in osteochondral allo-
grafts, a host immune response against chondrocytes has
not been reported. It is thought that the environmental
characteristics of articular cartilage such as avascular
and alymphatic extracellular matrix surrounding them
plays a role. The extracelluar matrix can shield the
MHC molecules from recognition by host cells; thereby
protecting the chondrocytes from host immune re-
sponses [13, 14]. The results are same with xenogeneic
transplantation. When human neocartilage was trans-
planted into surgical defects created in the knee joint in
genetically unrelated recipients, it was not rejected [15, 16].
Human juvenile chondrocytes present in bioengineered
neocartilage lack cell surface markers required for immune
responses. They do not induce alloantigen specific prolifer-
ative immune responses in vitro, and they actively suppress
the proliferation of activated T cells in a cell to cell
contact-dependent manner. These results suggest that the
immunosuppressive properties of chondrocytes may help
immune evasion of allograft [17].
As described previously, the hChonJ cells were derived
from very young donor (1 year-old), therefore it is possible
that hChonJ cells would share the immunosuppressive
properties of human juvenile chondrocytes. However,
hChonJ cells were cultured in monolayer and dedifferen-
tiated, so we cannot be sure whether they preserve the
properties of juvenile chondroctyes. In this study, we
investigated the cell surface marker expression related to
immune reaction and immunological properties of
hChonJ cells, the live cell component of Invossa™.
Methods
Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) with high
glucose, RPMI-1640, 1x antibiotic-antimycotic solution,
and trypsin–EDTA solution were purchased from Gibco
(CA, USA). Fetal bovine serum (FBS) was purchased
from Hyclone (UT, USA). Antibodies for FACS analysis,
including Isotype IgG1, IgG2a, HLA-ABC (MHC class
I), HLA-DR (MHC-class II), CD80 (B7-1), CD86 (B7-2),
CD137L (4-1BBL), CD152 (CTLA-4), CD252 (OX40L),
CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), CD279
(PD-1) and B7H4 were purchased from BD Biosciences
(CA, USA). Also, CD274 (PD-L1) and CD273 (PD-L2)
antibodies were purchased from eBioscience (CA, USA).
The detailed information of used antibodies was summa-
rized in Table 1. Recombinant interferon (IFN)-γ was
purchased from Peprotech (NJ, USA), isopropyl alcohol,
mitomycin C and phytohemagglutinin were purchased
from Sigma Chemical (MO, USA) and 3H-thymidine
was purchased from American Radiolabeled Chemicals
(MO, USA). Other materials included SuperScript™III
First-Strand Synthesis System and Trizol from Invitrogen
(CA, USA), PCR reagents from TAKARA Bio (Shiga,
Japan) and Ficoll-Paque PLUS from GE Healthcare
(Sweden).
Cell culture
hChonJ cells were cultured at Wuxi AppTec (Philadelphia,
PA, USA) in accordance with Good Manufacturing
Practices in DMEM supplemented with 10% heat-
inactivated FBS and antibiotic-antimycotic solution. As
the positive control for MHC class I, II, CD80 and CD86
molecule, Raji cells were cultured in RPMI-1640 supple-
mented with 10% heat-inactivated FBS and antibiotic-
antimycotic solution. For IFN-γ treatment, hChonJ cells
were incubated in the presence of 300 IU/mL of INF-γ for
96 h.
Flow cytometric analyses
The expression of immune-related cell surface markers
was analyzed by flow cytometry using the FACSCanto™
II (BD Biosciences). Cells were washed with PBS and in-
cubated with respective monoclonal antibody (mAb) or
the isotype control for 30 min in the dark at 4 °C. Then,
cells were washed and resuspended in PBS, and analyzed
on the FACSCanto™ II using FACS DIVA software. The
fluorescence intensity of each antibody was compared
with that of the isotype control and represented as a
Table 1 Antibody clones and isotypes
Antibody name Clone Isotype
HLA-ABC G46-2.6 Mouse IgG1, kappa
HLA-DR G46-6 Mouse IgG2a, kappa
CD44 515 Mouse IgG1, kappa
CD73 AD2 Mouse IgG1, kappa
CD80 L307.4 Mouse IgG1, kappa
CD86 FUN-1 Mouse IgG1, kappa
CD90 5E10 Mouse IgG1, kappa
CD105 SN6 Mouse IgG1, kappa
CD137L (4-1BBL) C65-485 Mouse IgG1, kappa
CD151 14A2.H1 Mouse IgG1, kappa
CD152 (CTLA-4) BNI3 Mouse IgG2a, kappa
CD252 (OX40L) ik-1 Mouse IgG1, kappa
CD273 (PD-L2) MIH18 Mouse IgG1, kappa
CD274 (PD-L1) MIH1 Mouse IgG1, kappa
CD278 (ICOS) DX29 Mouse IgG1, kappa
CD279 (PD-1) MIH4 Mouse IgG1, kappa
Mouse IgG1, kappa isotype control X40 Mouse IgG1, kappa
Mouse IgG2a, kappa isotype control X39 Mouse IgG2a, kappa
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histogram of measurements taken from each cell. These
experiments were performed three times independently.
mRNA analyses of cell surface molecules and indoleamine
2,3-dioxygenase (IDO)
The mRNA expression of cell surface molecules and
IDO was assessed using a reverse-transcription polymer-
ase chain reaction (RT-PCR). All primers were ordered
from Macrogen (Seoul, Korea). The sequences of
primers are shown in Table 2. Total RNA was extracted
using TriZol according to the manufacturer’s instruc-
tions. cDNA was synthesized by using SuperScript™ III
First-Strand Synthesis System. The procedures were as
follows: 1 μg of total RNA, 1 μL of 50 μM oligo(dT) pri-
mer, and 1 μL of 10 mM dNTP mix adjusted to a total
volume of 10 μL with DEPC-treated water. Mixtures were
incubated for 5 min at 65 °C; then, 2 μL of 10x RT buffer,
4 μL of 25 mM MgCl2, 2 μL of 0.1 M DTT, 1 μL of
RNaseOUT™, and 1 μL of SuperScript™ III RT were added
to each tube. The reaction was run in a BioRad thermocy-
cler for 50 min at 50 °C and 5 min at 85 °C; then, PCR
was performed using 2 μL of cDNA, 2 μL of 100 μM gene
specific primers, 10x PCR buffer, 2.5 mM dNTP mix,
5 U/μL Taq polymerase adjusted to a total volume of
20 μL with distilled water. PCR conditions included initial
denaturation step at 95 °C for 5 min, followed by 40 cycles
of denaturation at 95 °C for 30 s, annealing for 30 s and
extension at 72 °C for 1 min. Amplification was finished
with extension at 72 °C for 5 min. A housekeeping
gene β-actin was used as an internal control.
The expression of IDO mRNA was also assessed using
a quantitative reverse transcripion-polymerase chain re-
action (qRT-PCR). All primers were ordered from
Macrogen and the sequences of primers are shown in
Table 3. β-actin was used to normalize for IDO mRNA
expression. cDNA was synthesized as described above
for RT-PCR of IDO mRNA. Quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) was
performed with 2 μL of synthesized cDNA by using the
SYBR premix EX taq (TAKARA Bio) according to the
manufacturer’s instruction. The reactions were run on a
Rotor-gene Q system (Qiagen, Hilden, Germany) in trip-
licate. PCR conditions included initial denaturation step
at 95 °C for 5 min, followed by 40 cycles of denaturation
at 95 °C for 10 s, annealing at 58 °C for 15 s and
extension at 72 °C for 20 s. The quantification data were
analyzed with the Rotor Gene software to obtain relative
IDO expression and PCR products were examined for
the presence of by‑products using the melting curve
analysis provided by the software.
Mixed lymphocyte reaction (MLR) assay
Immunogenicity of hChonJ cells was assessed using an
MLR assay. In this MLR assay, we used hChonJ cells as
the stimulator, and MHC-mismatched peripheral blood
mononuclear cells (PBMCs) as the responder. Another
MHC-mismatched PBMCs were used as the stimulator
for a positive control of MLR assay. Human PBMCs
were obtained by density gradient centrifugation using
Ficoll-Paque™ PLUS according to the manufacturer’s in-
structions. Stimulator cells (hChonJ cells and PBMCs
obtained from MHC-mismatched donor) were treated
with 40 μg/mL of mitomycin C (MMC) to prevent cell
proliferation. 1 × 105 responder PBMCs were co-
cultured with 1 × 105 cells of MMC treated stimulator
PBMCs or various numbers of MMC treated hChonJ
cells (1 × 103, 1 × 104 and 5 × 104 cells) in triplicate in
round bottom 96-well plates (Nunc, Roskilde, Denmark).
To confirm the mitogenic activity of responder PBMCs,
the cells treated with 2 μg/mL of phytohemagglutinin
(PHA) were also cultured. Cell culture for MLR assay was
performed in RPMI-1640 supplemented with 10% FBS
and antibiotic-antimycotic solution for 4 days at 37 °C.
Eighteen hours before the end of culture, 0.5 μCi/well of
Table 2 PCR primers
Gene name Sequence Amplicon size (bp)
HLA-ABC (MHC class I) Sense, 5′-GATTCTCCCCAGACGCCGAG-3′
Antisense, 5′-CCTGGGCACTGTCACTGCTT-3′
1082
CD274 (PD-L1) Sense, 5′-CTACCCCAAGGCCGAAGTCA-3′
Antisense, 5′-CCCAGAATTACCAAGTGAGTCC-3′
258
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3H-thymidine was added to each well to measure the pro-
liferation of responder PBMCs. Then, cells were harvested
using an automated cell harvester (Tomtec, Hamden,
CT), and thymidine incorporation was measured by
Wallac MicroBeta-2 Scintillation Counter (PerkinElmer,
Boston, MA).
Immune suppression assays
The immune suppressive activity of hChonJ cells was
assessed using an allogeneic MLR assay. To evaluate
their ability to inhibit the proliferation of responder
cells, hChonJ cells (1 × 103, 1 × 104 and 5 × 104 cells/
well) were added to an allogeneic MLR culture for 4 days.
In addition, to evaluate whether the immune suppressive
mechanism is caused by cell to cell interaction or soluble
factors, assays were performed in two different culture
conditions. First, hChonJ cells (1 × 103, 1 × 104 and 5 ×
104 cells/well) were added to an allogeneic MLR culture
with 20 μL of antibodies against PD-L1 and/or PD-L2 to
mask co-inhibitory molecules expressed on hChonJ cells.
Second, allogeneic MLR cultures were separated from
hChonJ cells using transwell plate with a 0.2 μm pore
membrane (Nunc, MA, USA). Cells were cultured for
4 days, and 0.5 μCi/well of 3H-thymidine was added to
each well 18 h before the end of culture.
Statistical analysis
Statistical analysis was performed using Sigma Plot
(version 13.0) software. All data are presented as the
mean ± SE. Statistically significant differences among
study groups were determined by one-way analysis of
variance (ANOVA) and Tukey’s test was applied as a
post hoc test if statistical significance was determined.
Statistical significance was defined as P < 0.05.
Results
Expression of cell surface molecules on hChonJ cells
As the first step to evaluate the immunological property
of hChonJ cells, we investigated cell surface marker ex-
pression related to immune response, such as major
histocompatibility complex (MHC) class I, class II, co-
stimulatory molecules and co-inhibitory molecules. Flow
cytometry analysis showed that hChonJ cells expressed
MHC class I (HLA-ABC), but not MHC class II (HLA-
DR), which was expected because non-immune cells
usually express only MHC class I (Fig. 1a). hChonJ cells
did not express any of co-stimulatory molecules, such as
B7-1 (CD80) and B7-2 (CD86) (Fig. 1b), whose signals
are critical for T cell activation. We also measured the
expression of other co-stimulatory molecules, CD137L
(4-1BBL), CD252 (OX40L), CD278 (ICOS), but none of
these molecules were expressed on hChonJ cells
(Additional file 1: Figure S1). When the expression of
co-inhibitory molecules was analyzed, CD28/CTLA-4
family molecules, B7-H4, CD152 (CTLA-4), PD-1, and
PD-L1 was not detected on hChonJ cells (Additional file 1:
Figure S1). However, hChonJ cells expressed low levels of
PD-L2 by flow cytometry and RT-PCR (Fig. 1c, d). To
observe whether the passage of hChonJ cells could impact
on the cell surface marker expression, we passaged hChonJ
cells in monolayer for 3 additional times, and repeated flow
cytometric analysis. As a result, the expression patterns
were not changed when hChonJ cells were further pas-
saged (Additional file 2: Figure S2).
We evaluated the changes in cell surface marker ex-
pression after culturing hChonJ cells in the presence of
IFN-γ for 96 h. The expression level of MHC class I was
increased by IFN-γ (Fig. 2a). MHC class II molecules
were not expressed prior to IFN-γ treatment, but more
than 90% of cells became MHC class II positive after
IFN-γ treatment (Fig. 2a). However, there was no change
in the expression of the co-stimulatory molecules, CD80
and CD86 (Fig. 2b). We observed that the expression of
co-inhibitory molecules PD-L1 and PD-L2 was highly
up-regulated when hChonJ cells were treated with IFN-γ
(Fig. 2c).
The immunosuppressive properties of hChonJ cells on a
mixed lymphocyte reaction
In this study, we examined the immunogenicity of hChonJ
cells ex vivo using MLR assays. For the reaction, we used
non-dividing hChonJ cells treated with MMC as stimula-
tor cells and allogeneic human PBMCs as responder cells,
and we used non-dividing allogeneic PBMCs treated with
MMC for positive response of MLR. Three doses of non-
dividing hChonJ cells (1 × 103, 1 × 104 and 5 × 104 cells)
were mixed with 1 × 105 allogeneic responder PBMCs.
We observed that hChonJ cells did not elicit the prolifera-
tion of allogeneic responder PBMCs on day 4, while the
non-dividing allogeneic stimulator PBMCs induced robust
responder PBMC proliferation (Fig. 3a).
In order to investigate whether hChonJ cells can sup-
press alloreactive T cells, three doses of non-dividing
hChonJ cells (1 × 103, 1 × 104 and 5 × 104 cells) were
added to an MLR culture. We confirmed that hChonJ
cells could suppress allogeneic PBMC proliferation in a
dose-dependent manner (Fig. 3b) (p < 0.001).
To summarize, although hChonJ cells express MHC
class I molecules, they do not stimulate alloantigen-
specific T cell proliferation. Also, hChonJ cells have the
ability to suppress alloreactive T cells. In the following
Table 3 Quantitative real-time PCR primers
Gene name Sequence
IDO Sense, 5′- CTGGGCATCCAGCAGACT-3′
Antisense, 5′- TGAGCTGGTGGCATATATCTTCT-3′
β-actin Sense, 5′- CAACCGCGAGAAGATGAC-3′
Antisense, 5′- GTCCATCACGATGCCAGT-3′
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experiment, we investigated the mechanism of hChonJ
cells-mediated T cell suppression.
Mechanism of hChonJ cells-mediated immune
suppression
We tested whether the inhibition of T cell proliferation
by hChonJ cells was dependent on a cell to cell contact
mechanism or mediated by soluble molecules. hChonJ
cells expressed co-inhibitory molecules PD-L1 and PD-
L2 (Fig. 2c), which are known to regulate immune re-
sponse [18]. To examine if the inhibitory mechanism is
caused by cell to cell contact, non-dividing hChonJ cells
(5 × 104 cells) were added to an MLR culture with
neutralizing antibodies against PD-L1 and/or PD-L2 to
mask co-inhibitory molecules expressed on hChonJ cells.
Alloreactive T cell proliferation suppressed by hChonJ
cells was significantly restored by the blockade of PD-L2
(p = 0.006), and both PD-L1 and PD-L2 (p < 0.001)
(Fig. 4a). To examine if the inhibition is also caused by
soluble molecules, we performed an MLR in a trans-well
system where hChonJ cells were cultured in the upper
compartment, physically separated from MLR culture in
the lower compartment. We found that hChonJ cells did
not exert the suppressive effects on MLR without phys-
ical contact (Fig. 4b). These results suggested that the
immune suppression by hChonJ cells is mediated
Fig. 1 Flow cytometry analysis for immune-related surface marker on hChonJ. hChonJ cells were labeled with antibodies against immune-related
surface markers, including MHC class I (HLA-ABC), MHC class II (HLA-DR), co-stimulatory molecules (CD80 and CD86), co-inhibitory molecule,
(CD274 (PD-L1) and CD273 (PD-L2)) and immunoglobulin G1 isotype control. Raji cells were used as controls. hChonJ cells express MHC class I (a),
but not MHC class II (a) and co-stimulatory molecules CD80, CD86 (b). In addition, hChonJ express low level of PD-L2, but not PD-L1 (c). RT-PCR
confirmed the expression of PD-L2 in hChonJ (d). These results are the representative of at least 3 independent experiments
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Fig. 2 Flow cytometry analysis for the change of immune-related surface markers on IFN-γ treated hChonJ. After hChonJ cells were exposed to
300 IU/mL of IFN-γ, the cells were labeled with antibodies against immune-related surface markers, including MHC class I (HLA-ABC), MHC class II
(HLA-DR), co-stimulatory molecules (CD80 and CD86), co-inhibitory molecules (PD-L1 and PD-L2) and immunoglobulin G1 isotype control. The expression
of MHC class I and II molecules (a) was increased, but there was no change in the expression level of the co-stimulatory molecules CD80 and CD86 (b).
In the case of co-inhibitory molecules, PD-L1 expression was increased and the expression of PD-L2 was detected which was not expressed on IFN-γ
untreated hChonJ cells (c). These results are the representative of at least 3 independent experiments
Fig. 3 Immunogenecity and immunosuppressive effect of hChonJ. The immunogenicity and immunosuppressive effects of allogeneic hChonJ
cells were assessed using an MLR assay with allogeneic PBMCs that were isolated from a MHC mismatched donor. The proliferation of responder
PBMCs was measured with 0.5 μCi 3H-thymidine. hChonJ cells did not stimulate allogeneic T cell proliferation (a) and significantly suppressed
allogeneic T cell proliferation in a dose-dependent fashion (b). Bars represented the change of 3H-thymidine uptake in comparison with an
allogeneic MLR control (100%). Mean values from 4 independent experiments are illustrated (Mean ± SE)
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through a cell to cell contact not through soluble factors,
and PD-L1 and PD-L2 present on hChonJ cells play an
important role.
Expression of indoleamine 2,3-dioxygenase on
hChonJ cells
We investigated further if there are other mechanisms
responsible for the immunosuppressive activity of hChonJ
cells. We selected indoleamine 2,3-dioxygenase (IDO) as a
candidate because it is well-known that IDO can suppress
T-cell immune response by catabolizing the essential
amino acid tryptophan along the kynurenine pathway
from the cellular microenvironment [19–21]. In this study,
we investigated whether hChonJ cells express IDO. We
cultured hChonJ cells with or without IFN-gamma, and
performed RT-PCR to detect IDO mRNA. As shown in
Fig. 5, we observed that hChonJ cells did not express IDO
mRNA under normal condition but did express IDO
mRNA when they were treated with IFN-gamma. We also
analyzed the expression of IDO mRNA by qRT-PCR.
When hChonJ cells were treated with IFN-gamma, the Ct
value of IDO mRNA was changed from baseline
undetected (Ct ≥ 40) to 19.47 (SD = 0.82). This result
confirmed the RT-PCR data showing that the IDO gene
expression was induced by IFN-gamma treatment in
hChonJ cells.
Discussion
Invossa™ is an allogeneic cell and gene medicine for
osteoarthritis, and injected to the arthritic knee joints.
Articular cartilage is avascular and alymphatic, and it
has a thick layer of extracellular matrix which can
protect chondrocytes from immune cells. However, in
osteoarthritic conditions, the immune-privileged nature
of articular cartilage can be lost due to the damage to
cartilage. Osteoarthritis has long been considered non-
inflammatory arthropathy [22]. However, the involve-
ment of an inflammatory component, which is marked
by symptoms such as joint pain and swelling, is now well
recognized. The inflammatory response occurring in the
synovial membrane of osteoarthritic patients exhibits
features of a T cell immune response [23]. It has been
reported that CD3 positive T cells infiltrate in the
synovium of osteoarthritic patients [24] and T helper
cells promote disease progression of osteoarthritis [25].
Therefore, an antigen-driven immune response exists in
osteoarthritic patients. T cells, with chronic inflamma-
tory conditions, might be responsible for chondrocytes
degeneration or hyaluronic acid degradation [24].
In this study, we investigated the immunogenicity of
dedifferentiated allogeneic chondrocytes (hChonJ cells)
and found that hChonJ cells did not induce a T cell
response, but rather could suppress an immune
Fig. 4 Immunosuppressive mechanism of hChonJ. In order to investigate the mechanism involved in the suppression of T cell proliferation
mediated by hChonJ cells, we evaluated whether this phenomenon was dependent on a cell to cell contact or soluble molecules. To study the
involvement of the cell to cell contact mechanism, antibodies against PD-L1 and/or PD-L2 were directly added to the MLR culture. The involvement of
soluble molecules was studied by using a trans-well system where hChonJ (upper compartment) was physically separated from the MLR culture (lower
compartment). The proliferation of responder PBMCs was measured with 0.5 μCi 3H-thymidine. Alloreactive T cell proliferation that was suppressed by
hChonJ cells was significantly restored by treatment of PD-L1 and/or PD-L2 antibodies (a), but hChonJ cells did not exert their suppressive effects on
MLR culture in a trans-well system (b). Bars represented the change of 3H-thymidine uptake in comparison with an allogeneic MLR control (100%).
These results are the representative of 3 independent experiments (Mean ± SE)
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response. First, we tested the expression of cell surface
molecules on hChonJ cells and observed that they
expressed MHC class I, but did not express MHC class II
and co-stimulatory molecules, CD80 and CD86 (Fig. 1a, b).
Interestingly, hChonJ cells expressed co-inhibitory
molecule PD-L2 (Fig. 1c, d). PD-L2 expression is known to
be restricted to dendritic cells and macrophages,
although PD-L1 is expressed on both hematopoietic
cells and non-hematopoietic cells. PD-L2 expression in
non-hematopoietic cells was reported in human umbilical
vein endothelial cells (HUVEC) by flow cytometry [26]
and chondrocytes by RT-PCR [17]. However, this is the
first report that PD-L2 was constitutively expressed on
human chondrocytes at the protein level. We observed
that 20 – 30% of hChonJ cells expressed PD-L2 by flow
cytometry. We also analyzed the expression of cell surface
molecules on TGF-β 1 overexpressing chondrocytes, and
observed that there was no difference in the expression
pattern between hChonJ cells and TGF-β 1 overexpressing
cells (data not shown).
In addition, when hChonJ cells were exposed to IFN-
gamma, the expression of PD-L1 as well as that of PD-L2
was up-regulated (Fig. 2c). Both molecules were reported to
be up-regulated mainly upon exposure to IFN-γ in mono-
cytes, dendritic cells and cancer cells, however, it was not
reported in chondrocytes at the protein level [27–31].
These two co-inhibitory molecules, PD-L1 and PD-L2,
can suppress activated T cells through binding with PD-1
and it is known that cancer cells use this strategy to evade
host immune response. Our results indicate the possibility
that hChonJ cells can suppress activated T cells via these
co-inhibitory molecules.
We also tested the immunogenicity and immunosup-
pressive effect of hChonJ cells by using MLR assays.
When hChonJ cells were co-cultured with allogeneic
PBMCs, hChonJ cells did not stimulate alloantigen-
specific T cell proliferation (Fig. 3a). In order to investi-
gate whether hChonJ cells can suppress alloreactive T
cells, we added hChonJ cells to allogeneic MLR culture.
As shown in Fig. 3b, hChonJ cells significantly suppressed
allogeneic T cell proliferation in a dose-dependent
manner. We already knew that hChonJ cells express co-
inhibitory molecules, PD-L1 and PD-L2, which can
suppress the activated T cells. Here, we investigated
whether the suppression of T cell proliferation by hChonJ
cells is mediated by a cell to cell contact through PD-L1
and/or PD-L2. We used anti-PD-L1 and/or PD-L2 anti-
body to block its interaction with PD-1 on activated T cell.
The blockade of PD-L1 and/or PD-L2 with specific anti-
body led to restoration of alloreactive T cell proliferation
(Fig. 4a). When both anti-PD-L1 and anti-PD-L2 antibody
was present, T cells proliferation was significantly restored.
However, these two antibodies did not affect the allogen-
eic MLR by MMC-treated stimulator PBMCs (data not
shown). To investigate whether soluble factors secreted by
hChonJ cells are also involved in suppression of T cell pro-
liferation, we performed an MLR in flat-bottom, trans-
well system. However, in this system, hChonJ cells did not
exert their suppressive effects on MLR culture (Fig. 4b).
Therefore, interactions of the PD-L1, PD-L2 and PD-1,
which are delivered by direct contact between hChonJ
cells and allogeneic T cells, are required to weaken T cell
proliferation.
We further searched other molecules involved in T cell
suppression by hChonJ cells, and found out that IDO
might play a role in this phenomenon. IDO is one of the
major immunosuppressive molecules that inhibit T-cell
immune response against alloantigens [32, 33]. It catabo-
lizes tryptophan to kynurenine, resulting in localized de-
pletion of tryptophan and inhibition of cell proliferation.
The expression of IDO was reported in various cells.
BM-MSCs can inhibit an allogeneic T cell response
Fig. 5 RT-PCR analysis for indoleamine 2,3-dioxygenase (IDO). IDO mRNA expression in hChonJ was analyzed by RT-PCR. The RT-PCR results
showed the expression of IDO mRNA was induced by IFN-gamma treatment. Beta-actin mRNA served as an internal control
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through the expression of IDO [34]. Also, Adkisson and
the colleagues suggested IDO expression as a mechan-
ism of neocartilage implant survival [17]. We found out
that hChonJ cells also express IDO (Fig. 5). IDO
expression might be involved in the immunosuppressive
activity of hChonJ cells like the case of MSC or neo-
cartilage. We did not evaluate the expression of other
immunosuppressive molecules such as arginase or iNOS
in ChonJ cells. This possibility should be clarified in
further study.
In this report, we studied the immunogenicity of
human chondrocytes obtained from one donor. The
immunogenic properties observed in hChonJ cells may
not be repeated in other chondrocytes obtained from
other sources. This is the limit of our report, and we hope
that our research will be the basis for further research.
Conclusions
The hChonJ cells are not immunogenic and can sup-
press alloreactive T cell proliferation. It is known that
chondrocytes have immunosuppressive effect, and has
been surmised that co-inhibitory molecule are involved
[16]. However, there have been no reports showing the
involvement of PD-L1 and PD-L2 in the immunosup-
pression of chondrocytes. Here, we showed the PD-L1
and PD-L2 were involved in the immunosuppressive ef-
fect of chondrocyte through a cell to cell contact. Be-
cause of these immunological properties, clinical
applications of allogeneic hChonJ cells would not induce
an immune response. We have not tested the persistence
of the effects on humans. However, we could deduce
that hChonJ cells did not stimulate immune response in
human from the fact that the efficacy of Invossa™ lasted
more than a year in clinical trials.
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